Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint

ACR Presentation by Lupus LA founder Daniel Wallace, MD

S.L.E. Lupus Foundation Board Member and Lupus LA founder Daniel Wallace, MD presented research at ACR demonstrating the effectiveness of a new sensitive composite measure of disease activity in lupus used successfully in two clinical trials.

Full story | All ACR news